TRADE WITH CONVICTION

Monday, October 19, 2026
RSS


← All Stories

Earnings
The Concrete Compounders: Why Small-Cap Construction Stocks Are Built to Last

Nobility Homes and Monarch Cement post stellar earnings with double-digit margins, proving regional operators can outshi…

Mar 15, 2026
Earnings
Adobe's Earnings Beat Not Enough: Why is ADBE Stock Under Pressure?

Adobe beat Q1 estimates with $6.06 EPS, yet shares sank. We analyze the hidden risks behind the headline numbers.

Mar 15, 2026
Earnings
The Lipstick Effect Is Cracking: Ulta's 14% Plunge Signals Retail Rot

Ulta Beauty's brutal 14% selloff reveals deep cracks in the consumer discretionary facade as the post-pandemum vanity tr…

Mar 14, 2026
Earnings
Ulta Beauty's Stumble: A Warning Sign for Consumer Discretionary Stocks?

Ulta Beauty's disappointing earnings signal potential trouble for consumer discretionary stocks amid economic uncertaint…

Mar 14, 2026
Earnings
SentinelOne's Breakdown: Time to Short the Cyber Rally?

SentinelOne's Q4 miss and weak guidance triggered a technical breakdown. Here's why the cybersecurity trade is losing mo…

Mar 13, 2026
Earnings
SentinelOne's Stumble: Is the Cybersecurity Boom Over?

SentinelOne's weak forecast is spooking investors. Is this a company-specific issue, or a sign of broader challenges for…

Mar 13, 2026
Earnings
Ulta Beauty's Stumble: Is the Lipstick Effect Losing Its Luster?

Ulta's 8% plunge signals deeper cracks in discretionary retail as the 'lipstick effect' faces its toughest test yet.

Mar 13, 2026
Earnings
Vertex's Kidney Breakthrough: A Rare Chance to Own a Compounding Machine

VRTX jumps 4% on Phase 3 trial success. Here's why long-term investors should view volatility as opportunity, not noise.

Mar 12, 2026
Earnings
Oracle's AI Bet Pays Off: Can ORCL Sustain Its Momentum?

Oracle crushed Q3 with $1.79 EPS vs $1.70 expected, sparking a 9% rally as AI infrastructure fears fade. Here's your dat…

Mar 12, 2026
Earnings
VRTX: Is Vertex Pharmaceuticals a Safe Haven in a Turbulent Market?

Vertex's 4% surge on kidney drug trial results highlights why long-term investors are finding shelter in this biotech gi…

Mar 12, 2026
Earnings
Oracle's AI Gambit Pays Off: Is ORCL a Must-Have Stock for the Long-Term Investor?

Oracle's Q3 earnings crush expectations, proving its cloud-AI pivot is more than just smoke and mirrors. Here's why $ORC…

Mar 12, 2026
Earnings
Oracle's Cloud Crusade Faces the Volatility Guillotine

As $ORCL prepares to report Q3 earnings, the database giant must prove its cloud pivot can deliver growth amid tech sect…

Mar 10, 2026